Peripheral Arterial Disease Clinical Trial
Official title:
Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention (PacTAP Study): A Double Blind, Randomized Control Study
The purpose of this study is to assess the safety and efficacy of administering intra-arterial paclitaxel in the femoropopliteal arteries via the TAPAS catheter following percutaneous revascularization to prevent restenosis.
Peripheral artery disease (PAD) of the lower extremities is an extremely prevalent disorder
and is an important cause of morbidity that affects more than 10 million people in the
United States. This disorder is typically caused by atherosclerosis that limits blood flow
to the limbs, particularly due to stenosis or occlusion of the superficial femoral artery
(SFA) and/or popliteal artery. Although many patients are asymptomatic or are treated with
lifestyle changes, such as exercise therapy, or pharmacological treatment, including statins
and anti-platelet therapy, about 10-15% of patients have progressive symptoms which in
severe cases may lead to amputation.
Endovascular treatment with percutaneous vascular intervention (PVI), which includes
percutaneous transluminal angioplasty (PTA), stenting, atherectomy and thrombolytic therapy,
can provide excellent acute success rates greater than 90-95% However, the intermediate to
long-term patency rates of these arteries is hampered by neointimal hyperplasia resulting in
restenosis of the artery. This occurs with all endovascular therapy to some degree in both
the coronary and peripheral arena. With PVI in the superficial femoral and popliteal
arteries the restenosis rates are approximately 30-40% at 12 months, depending on the
complexity and severity of the disease.
In the coronary field, stents are now coated with anti-restenotic pharmacologic agents (drug
eluting stents—DES) such as paclitaxel and sirolimus-like drugs that prevent neointimal
growth. There have been published reports of significant efficacy in preventing restenosis
in the SFA by coating balloons with paclitaxel (drug eluting balloons—DEB) as well as a
nitinol stent. Despite the fact that these products are CE Mark approved and available in
Europe, currently there are no US FDA approved drug-eluting devices for use in PVI. Thus,
there remains a need for an alternative therapy to prevent restenosis in the SFA following
endovascular intervention.
Administration of intra-arterial paclitaxel mixed with iodinated contrast has been shown to
inhibit restenosis in a porcine coronary model.
Delivering paclitaxel intra-arterially in the coronary tree following stent implantation has
shown benefit in reducing the incidence of restenosis. The novel Targeted Adjustable
Pharmaceutical Application System (TAPAS)—TAPAS Catheter Therapeutic Infusion System
(ThermopeutiX, San Diego, CA, USA)—is a drug delivery catheter that consists of a proximal
and distal occlusion balloon with an adjustable length that allows a drug to dwell in a
specific segment of the artery for a period of time. The drug can then be aspirated and
discarded to avoid systemic exposure.
The PacTAP study is a randomized, double blind, placebo-control study to assess the safety
and efficacy of delivering intra-arterial paclitaxel via the TAPAS catheter following PVI to
prevent restenosis.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
| Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
| Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
| Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
| Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
| Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
| Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
| Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
| Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
| Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
| Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
| Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
| Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
| Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
| Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
| Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
| Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
| Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
| Completed |
NCT02384980 -
Saving Life and Limb: FES for the Elderly With PAD
|
Phase 1 |